[1] Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res, 2003, 27(2): 95-120.
[2] 陈其文, 田丹杏, 周永明. 骨髓增生异常综合征治疗进展. 医学研究杂志, 2010, 39(8): 119-123.
[3] Matarazzo MR, De Bonis ML, Strazzullo M, Cerase A, Ferraro M, Vastarelli P, Ballestar E, Esteller M, Kudo S, D'Esposito M. Multiple binding of methyl-CpG and poly-comb proteins in long-term gene silencing events. J Cell Physiol, 2007, 210(3): 711-719.
[4] Issa JP. Epigenetic changes in the myelodysplastic syn-drome. Hematol Oncol Clin North Am, 2010, 24(2): 317-330.
[5] Zhou L, Opalinska J, Sohal D, Yu YT, Mo YK, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang JH, Kambhampati S, Parmar S, Nischal S, Hueck C, Suzuki M, Freidman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, McMahon C, Gore SD, Pla-tanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem, 2011, 286(28): 25211-25223.
[6] Wu XQ, Liu WL, Tian Y, Xiao M, Wu Y, Li CR. Aberrant Methylation of Death-Associated Protein Kinase 1 CpG Islands in Myelodysplastic Syndromes. Acta Haematol, 2011, 125(4): 179-185.
[7] Fabiani E, Leone G, Giachelia M, D'alo' F, Greco M, Criscuolo M, Guidi F, Rutella S, Hohaus S, Voso MT. Analysis of genome-wide methylation and gene expression induced by 5-aza-2’-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma, 2010, 51(12): 2275-2284.
[8] 叶雪石, 刘霆. P15NK4B基因甲基化与骨髓增生异常综合征. 国外医学: 输血及血液学分册, 2004, 27(1): 63-67.
[9] Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelo-dysplasia and acute myeloid leukemia. Leukemia, 2003, 17(9): 1813-1819.
[10] Shen LL, Kantarjian H, Guo Y, Lin E, Shan JQ, Huang XL, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JPJ. DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes. J Clinical On-col, 2010, 28(4): 605-613.
[11] Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol, 2011, 7(5): 661-672.
[12] Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One, 2011, 6(3): e17388.
[13] Giachelia M, D'Alò F, Fabiani E, Saulnier N, Di Ruscio A, Guidi F, Hohaus S, Voso MT, Leone G. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. Leukemia Res, 2011, 35(4): 465-471.
[14] Desmond JC, Raynaud S, Tung E, Hofmann WK, Hafer-lach T, Koeffler HP. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia, 2007, 21(5): 1026-1034.
[15] Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LB. Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update. Ecancermedicalscience, 2008, 2: 121.
[16] Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK. Azaciti-dine for treatment of patients with myelodysplastic syn-dromes (MDS): practical recommendations of the German MDS Study Group. Ann Hematol, 2010, 89(9): 841-850.
[17] Bordoni RE, Feinbe
